Project Grant RM1DA066307
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded $6.99 million to The Regents of the University of California, San Francisco under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a five-year research initiative examining methamphetamine (MA) use impacts on immune dysfunction and HIV reservoir transcription in people living with HIV on antiretroviral therapy (ART). Initiated July 15, 2025, and concluding May 31, 2030, this project...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Miami a $516,914 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on HIV infection of brain pericytes and the synergistic effects of methamphetamine use. The award, obligated on May 1, 2026, with completion targeted for February 28, 2031, supports a transdisciplinary investigation examining how methamphetamine modulates innate immune dysregulation,...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Miami School of Medicine Office of Research Administration a $164,190 project grant on August 19, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award supports research investigating dopamine dysregulation and oxidative stress mechanisms underlying cognitive impairment in individuals with concurrent HIV infection and methamphetamine use. The project will be...
- Federal Project Grant Award Summary The University of California, San Diego received a $1,387,755 project grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective March 1, 2026 through December 31, 2030. This research project investigates the intertwined epidemics of HIV-Associated Neurocognitive Disorders (HAND) and Opioid Use Disorder (OUD) in the context of fentanyl addiction. The funded research delivers scientific...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded $198,854 to the University of California, San Diego under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a longitudinal study examining trajectories of social isolation and loneliness among older adults living with HIV (Human Immunodeficiency Virus) who use methamphetamine. The two-year project, initiated August 1, 2025 and concluding July 31, 2027, will deliver research services including...
- Federal Project Grant Award Summary Father Flanagan's Boys' Home received a $2.18 million Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective April 1, 2026, through March 31, 2031. This research initiative will investigate the neurological pathways connecting chronic methamphetamine use to cognitive dysfunction in people with HIV (PWH). The project employs a multidisciplinary team science approach...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Johns Hopkins University a $668,423 Project Grant effective April 15, 2026, through March 31, 2028, under the Drug Use and Addiction Research Programs (CFDA 93.279). This grant supports integrated research to define MECOM (MDS1 and EVI1 Complex Locus Protein)-associated microglial mechanisms underlying HIV persistence and methamphetamine-induced neuroinflammation in people with HIV who use...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded $438,950 under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Board of Regents of the University of Nebraska, operating through the University of Nebraska Medical Center (UNMC) in Omaha. The award, made on May 1, 2026, supports an R21 exploratory/developmental research grant with a project completion date of April 30, 2028. The research investigates the mechanisms underlying polysubstance use (PSU)...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of California, San Diego $2,312,059 under the Drug Use and Addiction Research Programs (CFDA 93.279) on August 1, 2025, for a five-year project period extending through April 30, 2030. The grant supports "Breaking Barriers: Innovating HIV Elimination with Social Network Strategies and Routine Substance Use Screening," a hybrid Type I clinical trial designed to identify and engage...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded UC San Diego a $1,118,834 Project Grant on May 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and implement an innovative community-informed modeling framework addressing HIV and Hepatitis C Virus (HCV) prevention resource allocation for people who use drugs (PWUD). The project will deliver a novel integrated system comprising: (1) artificially intelligent...
The BRAIN-FRAME (Brain-Focused Research on Antiretrovirals and Methamphetamine) project grant, awarded by the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2.475 million in federal funding to UC San Diego to conduct a multidisciplinary 52-week research initiative addressing HIV treatment and methamphetamine use disorder. The project integrates implementation science, pharmacology, virology, immunology, and neuroscience methodologies to investigate how long-acting injectable antiretroviral therapy (LAI-ART) combined with medication-assisted treatment (MAT) for active methamphetamine use disorder affects brain health and viral suppression in people with HIV. The research is structured around three subgoals—clinical implementation, brain health phenotyping, and biological mechanisms—with four research teams studying the same cohort of participants across multiple disciplinary perspectives. The principal deliverables include evidence-based clinical implementation protocols for deploying LAI-ART and MAT in primary care HIV clinics, comprehensive neurobiological and neurocognitive phenotyping data characterizing changes in brain function and cognitive outcomes, and mechanistic findings on how these integrated treatment approaches alter immune responses, neuroinflammation, and blood-brain barrier integrity. The award period extends from May 15, 2026, through March 31, 2031, generating research outcomes designed to improve clinical care and neurological outcomes for people with HIV experiencing active methamphetamine use disorder—a population with documented challenges in medication adherence and durable viral suppression using standard oral antiretroviral regimens.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.5m | 5/8/26 |